Aardvark Therapeutics, Inc. (AARD) Fair Value 2026

AARD · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (20/100)

Quick Summary — As of 2026-08-28, Aardvark Therapeutics, Inc. (AARD) trades at $5.79. QOC: 6.1/10. Value Trap Risk: 20/100 (SAFE). 1/13 models active.

Key Facts

Ticker
AARD
Price
$5.79
Quality Score
6.1/10
Value Trap Risk
20/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give AARD?

1 Intrinsic Value Models vs. Current Price ($5.79)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $1.52 -73.7%

All Models Active

All 1 models are displayed above.

What Is Aardvark Therapeutics, Inc. (AARD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Aardvark Therapeutics, Inc.'s intrinsic value is estimated at $1.52. Trading at its current price of $5.79, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -73.7%.

What Do the Models Say About AARD?

1 of 13 models are currently active for AARD. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does AARD Rank in Biotechnology?

Among 625 Biotechnology stocks, AARD ranks #139 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Aardvark Therapeutics, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is AARD a Value Trap?

CirclFi's Value Trap algorithm assigns AARD a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Aardvark Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Aardvark Therapeutics, Inc. scores 6.1 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AARD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AARD's 1 active models, average confidence is 48%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Aardvark Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

STTKShattuck Labs, Inc.QOC 6.1TSHATaysha Gene Therapies, Inc.QOC 6.1IMRNImmuron LimitedQOC 6.1INMBINmune Bio Inc.QOC 6.1SILOSilo Pharma, Inc.QOC 6.1LPCNLipocine Inc.QOC 6.1CYDYCytoDyn Inc.QOC 5.1ANTXAN2 Therapeutics, Inc.QOC 4.5GLMDGalmed Pharmaceuticals Ltd.QOC 2.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: STTK · TSHA · IMRN · INMB · SILO · LPCN · CYDY · ANTX · GLMD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AARD?

7 companies across all industries closest to AARD’s Quality of Company score of 6.1/10.

REKRRekor Systems, Inc.QOC 6.1BKYIBIO-key International, Inc.QOC 6.1BBNXBeta Bionics, Inc.QOC 6.1OZKBank OZKQOC 6.1INVEIdentiv, Inc.QOC 6.1MMLPMartin Midstream Partners L.P.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: REKR · BKYI · BBNX · OZK · INVE · MMLP · NVDA

Where Does AARD Sit in CirclFi's Biotechnology Rankings?

AARD is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Aardvark Therapeutics, Inc.’s Valuation?

What is Aardvark Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Aardvark Therapeutics, Inc. (AARD). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AARD overvalued or undervalued right now?

At $5.79, 0 of 1 active models suggest AARD may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Aardvark Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.1 mean for AARD?

Aardvark Therapeutics, Inc.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AARD?

CirclFi analyzes AARD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is AARD a value trap in 2026?

Aardvark Therapeutics, Inc.'s Value Trap score is 20/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Aardvark Therapeutics, Inc. (AARD) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/AARD/ · Methodology
Primary sources for this AARD valuation
  • Financial statements: Aardvark Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001774857) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AARD as of ; valuations recomputed .